Cytogenetic and loss-of-heterozygosity (LOH) studies have demonstrated that deletions of the chromosome 3 short arm (3p) occur at very high frequency in all forms of lung cancer (universal loss in SCLC AND about-80% in NSCLC). These observation suggest that 3p encodes one or more tumor suppressor genes whose loss is critical to lung cancer development and progression. Data from our laboratory and others have demonstrated 4 separate, recurring homozygous deletion regions on 3p. Project 1 will investigate the role of 3p loss in lung cancer and pre-malignant lesions. A primary goal of t his project is the translation of our experimental results into clinically useful approaches. While the most sensitive diagnostic 3p reagents will come from the actual target genes, a major advance in both LOH and FISH detection will result, respectively, from the use of highly polymorphic PCR-based markers and hybridization probes closely representing the target gene regions. To accomplish this, we will precisely define the affected 3p intervals and develop additional corresponding polymorphic markers and FSH probes that will be applied to the analysis of tumors, dysplastic biopsies and sputa. Not only will these reagents provide a powerful means for detecting small 3p alterations in diagnostic sample but they will facilitate the molecular cloning of target genes through improved definition of critical regions. B working with a common set of samples, we will be able to correlate our 3p results with those of other SPORE members and inter-SPORE collaborators investigating chr 9, p53, RB, p16INK4, cyclin D1 and other chromosomal loci frequently affected in lung cancer. From these combined data, we hope to gain a comprehensive understanding of genetic changes which characterize each type of lung cancer or pre-neoplastic lesion, and to begin to address issues of prognosis and predictability. We will further characterize and conduct gene searches within two selected target regions (distal 3p21.3 and 3p12(13) that undergo recurrent homozygous deletion as well as well as perform functional assays of candidate tumor suppressor genes. This latter effort will include transfection experiments of candidate genes into lung cancer cell lines to determine their effect on growth and tumorigenesis. Lastly, we will identify the region of chromosome 3 which encodes a recently recognized inhibitor of telomerase activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058187-08S4
Application #
6657493
Study Section
Project Start
2000-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
$61,783
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105

Showing the most recent 10 out of 435 publications